ArticleWorld journal of gastrointestinal pharmacology and therapeutics2025
Somatostatin-based therapies for external gastrointestinal fistulas: Updated meta-analysis of randomized clinical trials.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Octreotide as A Bridge to Anti-TNF Therapy in Severe Fistulizing Crohn's Disease Complicated by A Clinically High-Output Enterocutaneous Fistula: A Case Report and Literature Review.European journal of case reports in internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExternal gastrointestinal fistulas (EGIFs) are serious postoperative complications associated with prolonged hospital stays, sepsis, malnutrition, and high mortality rates. Reducing gastrointestinal secretions with somatostatin or its analogues may facilitate fistula closure. The clinical effectiveness of these therapies, however, remains uncertain.
aimTo investigate the effectiveness of somatostatin-based therapy for EGIFs.
methodsA systematic review and meta-analysis (Prospero CRD420251054344) of nine randomized controlled trials (442 patients) compared somatostatin-based therapies with standard care in tertiary care settings. Protocols included somatostatin, octreotide, or lanreotide, administered at various dosages (250 micrograms/hour intravenous infusion or 100 micrograms subcutaneous injection three times daily) for 7 to 56 days. Primary outcomes were fistula closure rates and time to closure. Secondary outcomes were hospital length of stay, complications, need for surgical intervention, and mortality. Mean differences and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Risk of bias was assessed with the Cochrane RoB 2 tool.
resultsThere was no statistically significant difference in closure rate (RR: 1.11, 95%CI: 0.95-1.28,
conclusionSomatostatin-based therapies did not significantly improve fistula closure rates but were associated with shorter time to closure and hospital stay. Mortality, complications, and surgical intervention requirements remained unchanged, suggesting that these therapies may serve only as an adjunctive option in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.